Feature|Videos|November 10, 2026

Building Connected AI Ecosystems, Not Standalone Tools

Key Takeaways

  • Understand how to design AI ecosystems from the user back.
  • Learn how to map end-to-end workflows, including the tasks within them.
SHOW MORE

Experts consider what happens when artificial intelligence (A) tools multiply faster than organizations can connect them.

As AI adoption accelerates, many commercial organizations are managing a growing collection of point solutions. These solutions include overlapping tools for the same capability, users’ unsure which tool to use, information technology teams stretched by validation requirements, and mounting cost pressure. In this Peer Exchange® episode, Shankar Narayanan, CEO of Real Chemistry, Zoe Lazarra, CMO of Genetech, and Claudia Ciciliano, VP Digital Strategy & Product Operations at Bayerdiscuss why that model is difficult to sustain and what a connected ecosystem looks like in practice.

Narayanan explains that standalone tools provide capabilities, while connection provides context; context is what allows value to compound. He describes designing ecosystems from the user back. This allows people to articulate the problem they are trying to solve and be guided through the right sequence of tools, data, and context, with compliance guardrails built in at every step. Ciciliano distinguishes between a personal productivity lane of AI adoption and an end-to-end workflow lane. Widespread adoption and value come from mapping workflows, identifying where friction exists, and maintaining the resulting ecosystem through ongoing governance and optimization.

Lazarra offers a practical example: bringing first-party insights from field teams into marketing and insights engines in near real time. Without that connection, organizations risk automating their silos.


Related to this article

Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.